Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:SNCA Seneca Biopharma (SNCA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrends About Seneca Biopharma Stock (NASDAQ:SNCA) 30 days 90 days 365 days Advanced Chart Ad Crypto 101 MediaThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech giants are quietly integrating it. Venture capitalists are scrambling to invest.Click here to discover our #1 crypto for the market right now – poised for massive growth Get Seneca Biopharma alerts:Sign Up Key Stats Today's Range$2.30▼$2.5150-Day Range$1.39▼$10.2552-Week Range$0.50▼$2.67Volume36,749 shsAverage Volume3.78 million shsMarket Capitalization$41.16 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSeneca Biopharma, Inc., a clinical stage biopharmaceutical company, develops novel treatments for diseases of high unmet medical needs. The company's stem cell-based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as in Phase II clinical trial for the treatment of chronic ischemic stroke and in Phase I clinical trial for the treatment of chronic spinal cord injury; and NSI-189 that has completed Phase II clinical trials for the treatment of major depressive disorder. The company was formerly known as Neuralstem, Inc. and changed its name to Seneca Biopharma, Inc. in October 2019. Seneca Biopharma, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.Read More… The Crypto That’s Making Wall Street Sweat (Ad)The Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech giants are quietly integrating it. Venture capitalists are scrambling to invest.Click here to discover our #1 crypto for the market right now – poised for massive growth Receive SNCA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seneca Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address SNCA Stock News HeadlinesLeading BioSciences Inc, Seneca Biopharma, Inc. - M&A Call TranscriptMarch 2, 2024 | gurufocus.comLeading BioSciences, Inc., Seneca Biopharma, Inc. - M&A Call TranscriptMarch 2, 2024 | gurufocus.comTop "Sleeping Giant" Crypto In The Market NowTop "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future. November 12, 2024 | Crypto 101 Media (Ad)Seneca Foods Corp Class ADecember 16, 2023 | morningstar.comWest Seneca West Senior High SchoolApril 30, 2023 | usnews.comSeneca High SchoolApril 19, 2023 | usnews.com'This is a tragedy': Giraffe dies after getting caught in enclosure gate at New York zooFebruary 16, 2023 | usatoday.comSee More Headlines SNCA Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Seneca Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Seneca Biopharma investors own include iBio (IBIO), Matinas BioPharma (MTNB), Ocugen (OCGN), Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP), Bionano Genomics (BNGO) and Artelo Biosciences (ARTL). Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:SNCA CUSIPN/A CIKN/A Webwww.senecabio.com Phone(301) 366-4960FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,350,000.00 Net Margins-230.34% Pretax MarginN/A Return on Equity-122.20% Return on Assets-110.61% Debt Debt-to-Equity RatioN/A Current Ratio14.96 Quick Ratio14.96 Sales & Book Value Annual Sales$10,000.00 Price / Sales4,116.45 Cash FlowN/A Price / Cash FlowN/A Book Value$1.33 per share Price / Book1.79Miscellaneous Outstanding Shares17,296,000Free FloatN/AMarket Cap$41.16 million OptionableNot Optionable Beta1.83 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report This page (NASDAQ:SNCA) was last updated on 11/12/2024 by MarketBeat.com Staff From Our Partners[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredCritical warning from the mountains of CarolinaNvidia CEO Jensen Huang says Big Tech will spend over $1 trillion on data centers. And that still might not...Weiss Ratings | SponsoredCrypto’s FINAL Wealth MomentBitcoin’s final bull market is here. If you missed out on the gains in 2017, or 2021… 2025 stands to be jus...Paradigm Press | SponsoredWall Street’s “Secret” Land Grab33-year Wall Street veteran Dylan Jovine says there is one stock that could soar as high as 1,000% or more wit...Behind the Markets | SponsoredBreaking News: Are Trump/Musk Planning an AI Takeover? (Shocking)Now that he is Donald Trump’s right-hand man… You owe it to yourself to see Elon Musk’s big AI prediction f...Traders Agency | SponsoredRe: Last Call for You to Get Wednesday’s TradeImagine a trading strategy that works when stocks rise, fall, or stay the same. Our strategy gives you three w...StockEarnings | SponsoredDiversification is for dummies.I went 20 years on Wall Street without a single losing year... My former hedge fund, Banyan Capital, was ra...Opportunistic Trader | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seneca Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seneca Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.